The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume

Goto, Ryoichi; Ito, Makoto; Kawamura, Norio; Watanabe, Masaaki; Ganchiku, Yoshikazu; Kamiyama, Toshiya; Shimamura, Tsuyoshi; Taketomi, Akinobu

The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume

Goto, Ryoichi; Ito, Makoto; Kawamura, Norio et al.

Immunity, inflammation and disease, 2022, 10(3), e586

Permalink : https://hdl.handle.net/2115/84263

このアイテムのアクセス数:325件（2026-01-23 08:29 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1002/iid3.586

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/84263
タイトル	The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume
著者	Goto, Ryoichi ; Ito, Makoto ; Kawamura, Norio ; Watanabe, Masaaki ; Ganchiku, Yoshikazu ; Kamiyama, Toshiya ; Shimamura, Tsuyoshi ; Taketomi, Akinobu
e-Rad_Researcher 10645287 著者名 Goto, Ryoichi
著者名 Ito, Makoto
e-Rad_Researcher 20746953 著者名 Kawamura, Norio
著者名 Watanabe, Masaaki
著者名 Ganchiku, Yoshikazu
e-Rad_Researcher 80322816 著者名 Kamiyama, Toshiya
e-Rad_Researcher 00333617 著者名 Shimamura, Tsuyoshi
e-Rad_Researcher 70363364 著者名 Taketomi, Akinobu
言語	英語
キーワード	GV/SV ratio
	left hepatic lobe
	lymphocyte crossmatch test
	pre-transplantation
	small for size graft
発行日	2022-03
出版者	John Wiley & Sons
収録物名	Immunity, inflammation and disease
巻(号)	10(3)
ページ	e586
抄録	Introduction: The roles of preformed anti-HLA donor-specific antibodies (DSAs) in liver transplantation remain controversial. We evaluated the impact of preformed DSAs in living donor liver transplantation. Methods: Adults who underwent living donor liver transplantation (n = 175) in our institute were included in this study. Lymphocyte cytotoxicity test (LCT), flow cytometric crossmatch (FCXM), and single-antigen bead assays were performed. Results: Among adult living donor liver transplantation recipients, 27 (16.5%) and 14 (8.5%) had pretransplant FCXM-positive findings and LCT-positive findings, respectively. FCXM-positive patients displayed a significantly worse 5-year graft survival rate (77.3%; vs. DSA-negative, 91.6%). Six of 14 LCT-positive patients exhibited graft loss shortly after transplantation (5-year survival rate: 57.1%). All LCT-positive patients with graft loss underwent left lobe living donor liver transplantation. Significantly lower ratio of graft volume relative to standard liver volume (32.9 +/- 5.7%) and smaller graft size (365.3 +/- 57.9 g) were observed in patients with graft loss (p<.03, vs. surviving grafts). Significantly higher DSA-mean fluorescence intensity (MFI) values were present in patients with graft loss (p=.0012, vs. surviving grafts). Conclusions: Patients with preformed DSAs exhibited worse graft outcomes in living donor liver transplantation. Higher DSA-MFI values and smaller graft size were associated with worse outcomes in LCT-positive patients. High-risk patients with preformed DSAs should be considered for appropriate graft selection and application of a desensitization protocol.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1002/iid3.586